Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

Cross, 2019, B and T cell prolymphocytic leukaemia, Best Pract. Res. Clin. Haematol., 32, 217, 10.1016/j.beha.2019.06.001 Chaar, 2007, Complete response to alemtuzumab in a patient with B prolymphocytic leukemia [7], Am. J. Hematol., 82, 417, 10.1002/ajh.20843 Eyre, 2019, Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme, Br. J. Haematol., 184, 667, 10.1111/bjh.15151 Eyre, 2019, Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis, Br. J. Haematol., 185, 656, 10.1111/bjh.15802 J. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., 2008. Ravandi, 2005, Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment, Mayo Clin. Proc., 80, 1660, 10.4065/80.12.1660 Shvidel, 1999, B-Cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course, Leuk. Lymphoma., 33, 169, 10.3109/10428199909093739 Dearden, 2012, How I treat prolymphocytic leukemia, Blood, 120, 538, 10.1182/blood-2012-01-380139 Del Giudice, 2006, IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL), Leukemia, 20, 1231, 10.1038/sj.leu.2404238 Davi, 1996, High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia, Blood, 88, 3953, 10.1182/blood.V88.10.3953.bloodjournal88103953 Put, 2012, Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course, Ann. Hematol., 91, 863, 10.1007/s00277-011-1393-y Flatley, 2014, Aberrations of MYC are a common event in B-cell prolymphocytic leukemia, Am. J. Clin. Pathol., 142, 347, 10.1309/AJCPUBHM8U7ZFLOB Chapiro, 2019, Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53, Blood, 134, 1821 Döhner, 1993, Pentostatin in prolymphocytic leukemia: phase II trial of the European organization for research and treatment of cancer leukemia cooperative study group, J. Natl. Cancer Inst., 85, 658, 10.1093/jnci/85.8.658 Tempescul, 2009, A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia, Ann. Hematol., 88, 85, 10.1007/s00277-008-0541-5 Chow, 2011, Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia, Eur. J. Haematol., 87, 426, 10.1111/j.1600-0609.2011.01680.x McCune, 2002, Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia, Leuk. Lymphoma., 43, 1007, 10.1080/10428190290021597 Coelho, 2017, Sequential kinase inhibition (idelalisib/ibrutinib) induces clinical remission in b-cell prolymphocytic leukemia harboring a 17p deletion, Case Rep. Hematol., 2017, 1, 10.1155/2017/8563218 Gordon, 2017, Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia, Br. J. Haematol., 179, 501, 10.1111/bjh.14224 Bindra, 2019, B-cell prolymphocytic leukemia: case report and challenges on a diagnostic and therapeutic forefront, Cureus., 11 Oka, 2020, Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia, Invest. New Drugs., 38, 1598, 10.1007/s10637-020-00902-9 Jain, 2019, Ibrutinib and Venetoclax for First-Line Treatment of CLL, N. Engl. J. Med., 380, 2095, 10.1056/NEJMoa1900574